Search Results

LINZONOR 600 #

LINEZOLID 600mg. IP

Send Enquiry

MEDANOR

Tablets

Packaging and packing Type

Alu Strip | 10x1x4

MRP :

₹141.5

PTR :

₹101.07

PTS :

₹90.96

The first member of a new generation of antibiotics, the synthetic oxazolidinones, approved for the treatment of Gram-positive bacterial infections, i... Read More

Composition

LINEZOLID 600mg. IP

Send Enquiry

India’s Largest Pharma Franchise

100%

Genuine Products

Secure

Payments

24 x 7

Customer Support

About the product

Description

The first member of a new generation of antibiotics, the synthetic oxazolidinones, approved for the treatment of Gram-positive bacterial infections, including resistant strains. (Andrzej Jankowski, 2006) Plays an important role in the management of serious gram-positive infections including methicillin-resistant staphylococci, penicillin-resistant pneumococci, and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. (C M Perry, 2001) Acts as a bacteriostatic against some species (e.g., enterococci) and bactericidal against others (e.g., pneumococci). (R Norrby, 2001) As effective as clarithromycin 250mg or cefpodoxime proxetil 200mg in the treatment of patients with uncomplicated skin and soft tissue infections or community-acquired pneumonia.(C M Perry B. J., 2001) An effective therapy as intravenous vancomycin 1 g in the treatment of patients with hospital-acquired pneumonia and those with infections caused by methicillin-resistant staphylococci. (D Clemett, 2000) A valid therapeutic option for treating both community and hospital-acquired infections due to multiresistant Gram-positive cocci. (G Corti, 2000) A safe and effective treatment for adult liver transplant patients with gram-positive bacterial infections. (S Radunz, 2011) A promising drug for the treatment of prosthetic joint infections due to methicillin-resistant Staphylococcus aureus or other Gram-positive pathogens, especially a long-term antibiotic therapy is required. (M Bassetti, 2001) Superior clinical cure rates for the treatment of skin and soft tissue infections 88.1 % with linezolid and 86.1 % with penicillinase-stable penicillins. (W A Krueger, 2002) Has similar safety and efficacy to teicoplanin in treating Gram-positive infections in critically ill patients. (Jorge A Cepeda, 2004) More effective than glycopeptides, macrolides, and beta-lactams for skin and soft tissue infections. (Matthew E Falagas, 2008)

Side Effects

Vomiting, Headache, Nausea, Decreased blood cells (red cells, white cells, and platelets), Diarrhea

Indication

Treats bacterial infections: , Nosocomial pneumonia or hospital-acquired pneumonia , Community-acquired pneumonia , Complicated and uncomplicated skin and skin structure infections , Vancomycin-resistant Enterococcus infections , Methicillin-resistant staphylococci infections , Penicillin-resistant pneumococci infections

Important Notice

Temp data

Storage Condition

Product details for storage condition Product details for storage condition Product details for storage condition Product details for storage condition

Looking into the future of healthcare

Contact

Plot No 4, HSIIDC IT PARK, Sector 22,Panchkula, Haryana, India 134109

Phone: 9888988858

Business Hours

Mon-Sat: 9AM to 6PM

Franchise Enquiry

Request a callback to get more information about becoming a PCD Franchise Owner***

    Send Enquiry

    Request a callback to get more information about becoming a PCD Franchise Owner